ECSP11011032A - Pirrolidinas - Google Patents
PirrolidinasInfo
- Publication number
- ECSP11011032A ECSP11011032A EC2011011032A ECSP11011032A ECSP11011032A EC SP11011032 A ECSP11011032 A EC SP11011032A EC 2011011032 A EC2011011032 A EC 2011011032A EC SP11011032 A ECSP11011032 A EC SP11011032A EC SP11011032 A ECSP11011032 A EC SP11011032A
- Authority
- EC
- Ecuador
- Prior art keywords
- compounds
- formula
- preparation
- pelvic pain
- chronic pelvic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere a una clase de compuestos de pirrolidina de fórmula (I), y sus derivados farmacéuticamente aceptables, a su uso en medicina, a composiciones que los contienen, y a procesos para su preparación. También se refiere a intermedios utilizados en la preparación de dichos compuestos y derivados. En particular, los compuestos de fórmula (I) son útiles para el tratamiento de trastornos mediados por EP2, como la endometriosis, los fibroides uterinos (leiomiomata), la menorragia, la adenomiosis, la dismenorrea primaria y secundaria (incluyendo los síntomas de dispareunia, disquexia y dolor pélvico crónico), el síndrome del dolor pélvico crónico, la enfermedad del riñón poliquístico y el síndrome del ovario poliquístico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11286908P | 2008-11-10 | 2008-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP11011032A true ECSP11011032A (es) | 2011-06-30 |
Family
ID=41503565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2011011032A ECSP11011032A (es) | 2008-11-10 | 2011-05-05 | Pirrolidinas |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8278343B2 (es) |
| EP (1) | EP2364296A1 (es) |
| JP (1) | JP2012508225A (es) |
| KR (1) | KR20110083733A (es) |
| CN (1) | CN102209710A (es) |
| AP (1) | AP2011005728A0 (es) |
| AR (1) | AR074314A1 (es) |
| AU (1) | AU2009312427B2 (es) |
| BR (1) | BRPI0920924A2 (es) |
| CA (1) | CA2741589A1 (es) |
| CL (1) | CL2011001034A1 (es) |
| CO (1) | CO6382112A2 (es) |
| CR (1) | CR20110217A (es) |
| CU (1) | CU20110093A7 (es) |
| DO (1) | DOP2011000127A (es) |
| EA (1) | EA201100549A1 (es) |
| EC (1) | ECSP11011032A (es) |
| GE (1) | GEP20125607B (es) |
| IL (1) | IL212490A0 (es) |
| MA (1) | MA32782B1 (es) |
| MX (1) | MX2011004903A (es) |
| NI (1) | NI201100092A (es) |
| NZ (1) | NZ592311A (es) |
| PA (1) | PA8848001A1 (es) |
| PE (1) | PE20110663A1 (es) |
| SV (1) | SV2011003896A (es) |
| TN (1) | TN2011000211A1 (es) |
| TW (1) | TW201022234A (es) |
| UY (1) | UY32228A (es) |
| WO (1) | WO2010052625A1 (es) |
| ZA (1) | ZA201104310B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR074776A1 (es) * | 2008-12-18 | 2011-02-09 | Sanofi Aventis | Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente |
| TW201326154A (zh) | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑 |
| WO2013176220A1 (ja) * | 2012-05-25 | 2013-11-28 | 国立大学法人京都大学 | 概日リズム調整 |
| CN110041269A (zh) * | 2019-05-16 | 2019-07-23 | 海门瑞一医药科技有限公司 | 一种2-氯-5-羟基嘧啶的制备方法 |
| WO2022272062A1 (en) * | 2021-06-24 | 2022-12-29 | Reservoir Neuroscience, Inc. | Ep2 antagonist compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2078790C (en) * | 1991-01-21 | 1998-10-06 | Susumu Kamata | 3-benzylidene-1-carbamoyl-2-pyrrolidone analogues |
| WO2003053923A2 (en) * | 2001-12-20 | 2003-07-03 | Applied Research Systems Ars Holding N.V. | Pyrrolidine derivatives as prostaglandin modulators |
| WO2007005176A1 (en) * | 2005-06-29 | 2007-01-11 | Allergan, Inc. | Pyrrolidinones for the treatment of glaucoma and ocular hypertension |
| US7592364B2 (en) * | 2006-02-28 | 2009-09-22 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
| US7550448B2 (en) * | 2006-05-24 | 2009-06-23 | Allergan, Inc. | Therapeutic compounds |
| DE102006039912A1 (de) * | 2006-08-25 | 2008-03-20 | Bayer Healthcare Ag | Substituierte Spirotetronsäuren und ihre Verwendung |
| CN101679235A (zh) * | 2007-05-10 | 2010-03-24 | 辉瑞有限公司 | 氮杂环丁烷衍生物和它们作为前列腺素e2拮抗剂的用途 |
-
2009
- 2009-10-30 AP AP2011005728A patent/AP2011005728A0/xx unknown
- 2009-10-30 JP JP2011535189A patent/JP2012508225A/ja not_active Ceased
- 2009-10-30 PE PE2011001004A patent/PE20110663A1/es not_active Application Discontinuation
- 2009-10-30 MX MX2011004903A patent/MX2011004903A/es active IP Right Grant
- 2009-10-30 CA CA2741589A patent/CA2741589A1/en not_active Abandoned
- 2009-10-30 BR BRPI0920924A patent/BRPI0920924A2/pt not_active IP Right Cessation
- 2009-10-30 WO PCT/IB2009/054824 patent/WO2010052625A1/en active Application Filing
- 2009-10-30 AU AU2009312427A patent/AU2009312427B2/en not_active Ceased
- 2009-10-30 GE GEAP200912219A patent/GEP20125607B/en unknown
- 2009-10-30 NZ NZ592311A patent/NZ592311A/xx not_active IP Right Cessation
- 2009-10-30 CN CN2009801446055A patent/CN102209710A/zh active Pending
- 2009-10-30 EA EA201100549A patent/EA201100549A1/ru unknown
- 2009-10-30 KR KR1020117013231A patent/KR20110083733A/ko active IP Right Grant
- 2009-10-30 EP EP09756838A patent/EP2364296A1/en not_active Withdrawn
- 2009-11-06 US US12/613,771 patent/US8278343B2/en not_active Expired - Fee Related
- 2009-11-09 TW TW098137955A patent/TW201022234A/zh unknown
- 2009-11-09 UY UY0001032228A patent/UY32228A/es not_active Application Discontinuation
- 2009-11-09 PA PA20098848001A patent/PA8848001A1/es unknown
- 2009-11-10 AR ARP090104350A patent/AR074314A1/es not_active Application Discontinuation
-
2011
- 2011-04-25 CU CU20110093A patent/CU20110093A7/es unknown
- 2011-04-26 CR CR20110217A patent/CR20110217A/es unknown
- 2011-04-26 IL IL212490A patent/IL212490A0/en unknown
- 2011-04-29 TN TN2011000211A patent/TN2011000211A1/fr unknown
- 2011-05-05 EC EC2011011032A patent/ECSP11011032A/es unknown
- 2011-05-06 DO DO2011000127A patent/DOP2011000127A/es unknown
- 2011-05-06 SV SV2011003896A patent/SV2011003896A/es unknown
- 2011-05-09 NI NI201100092A patent/NI201100092A/es unknown
- 2011-05-09 CL CL2011001034A patent/CL2011001034A1/es unknown
- 2011-05-10 MA MA33829A patent/MA32782B1/fr unknown
- 2011-05-11 CO CO11058068A patent/CO6382112A2/es not_active Application Discontinuation
- 2011-06-09 ZA ZA2011/04310A patent/ZA201104310B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AP2011005728A0 (en) | 2011-06-30 |
| BRPI0920924A2 (pt) | 2016-10-04 |
| CL2011001034A1 (es) | 2011-11-11 |
| TN2011000211A1 (fr) | 2012-12-17 |
| AU2009312427B2 (en) | 2011-10-20 |
| IL212490A0 (en) | 2011-06-30 |
| PA8848001A1 (es) | 2010-06-28 |
| AU2009312427A1 (en) | 2010-05-14 |
| AR074314A1 (es) | 2011-01-05 |
| CR20110217A (es) | 2011-05-12 |
| GEP20125607B (en) | 2012-08-10 |
| WO2010052625A1 (en) | 2010-05-14 |
| CU20110093A7 (es) | 2012-01-31 |
| CA2741589A1 (en) | 2010-05-14 |
| NZ592311A (en) | 2012-12-21 |
| TW201022234A (en) | 2010-06-16 |
| EA201100549A1 (ru) | 2011-12-30 |
| JP2012508225A (ja) | 2012-04-05 |
| DOP2011000127A (es) | 2011-07-15 |
| UY32228A (es) | 2010-06-30 |
| CN102209710A (zh) | 2011-10-05 |
| ZA201104310B (en) | 2012-02-29 |
| EP2364296A1 (en) | 2011-09-14 |
| PE20110663A1 (es) | 2011-09-23 |
| CO6382112A2 (es) | 2012-02-15 |
| SV2011003896A (es) | 2011-07-05 |
| NI201100092A (es) | 2011-10-31 |
| US8278343B2 (en) | 2012-10-02 |
| US20100120793A1 (en) | 2010-05-13 |
| MX2011004903A (es) | 2011-05-30 |
| MA32782B1 (fr) | 2011-11-01 |
| KR20110083733A (ko) | 2011-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PA8827901A1 (es) | Derivados de quinoxalin- y quinolin-carboxamida | |
| CO6321265A2 (es) | Compuestos de 2-amido-3-metil pirrolo pirimidinona fenilo -sustituidos como inhibidores bace-1 composiciones y su uso | |
| ECSP11011032A (es) | Pirrolidinas | |
| CU24487B1 (es) | Compuestos de tetrahidroquinolinona sustituidos como moduladores de gamma ror | |
| SV2011003970A (es) | Derivados de sulfonamida | |
| CR11061A (es) | Derivados de piridina | |
| CY1116328T1 (el) | Παραγωγα 4 - αμινοπυριμιδινης και η χρηση τους ως ανταγωνιστων α2α υποδοχεων αδενοσινης | |
| GT201400079A (es) | Derivados de (4-fenilimidazol-2-il) etilamina útiles como moduladores de canal de sodio | |
| CL2020001097A1 (es) | Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
| CO6420342A2 (es) | Derivados de pirazol usados como antagonistas del receptor ccr4 | |
| SI3044206T1 (en) | (3Z, 5S) -5- (hydroxymethyl) -1 - ((2'-methyl-1,1'-biphenyl-4-yl) carbonyl) pyrrolidin-3-one O-methyloxymes as an antagonist of the oxytocin receptor antagonist V1a for vasopressin to treat premature labor | |
| UY28979A1 (es) | Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3 | |
| CR11101A (es) | Azetidinas | |
| ECSP10010606A (es) | Derivados de quinuclidina como antagonistas de receptores muscarinicos m3 | |
| ECSP22049160A (es) | Derivados de bencimidazol | |
| EA201890684A1 (ru) | Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1 | |
| AR071721A1 (es) | Derivados de piridil-prolinamida, composiciones farmaceuticas que los contienen y su uso para el tratamiento de ansiedad, depresion y trastornos del sueno. | |
| CR9595A (es) | Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona | |
| CO6690116A1 (es) | Nueva asociación entre la 4-[3-(cis-hexahidrociclopenta[c]pirrol -2(1h)-il]propoxi]benzamida y un antagonista de los receptores nmda y las composiciones famacéuticas que las contienen | |
| ATE525360T1 (de) | Neuartige imidazolinylmethyl-aryl-sulfonamide | |
| CR20170536A (es) | Derivados de etinilo | |
| CO6331339A2 (es) | Derivados de quinuclidina como antagonistas del receptor muscarinico m3 | |
| CU20100217A7 (es) | Derivados de quinuclidina como antagonistas de receptores muscarínicos m3 | |
| UY29409A1 (es) | Compuestos de la ftalazina, aza- y diaza-ftalazina y metodos de uso |